Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC.
Jto Clinical And Research Reports
Hondelink, Liesbeth M LM; Jebbink, Merel M; von der Thüsen, Jan H JH; Cohen, Danielle D; Dubbink, Hendrikus J HJ; Paats, Marthe S MS; Dingemans, Anne-Marie C AC; de Langen, Adrianus J AJ; Boelens, Mirjam C MC; Smit, Egbert F EF; Postmus, Pieter E PE; van Wezel, Tom T; Monkhorst, Kim K
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice.
Journal Of Thoracic Disease
González de Aledo-Castillo, José Manuel JM; Arcocha, Ainara A; Victoria, Iván I; Martinez-Puchol, Ana Isabel AI; Sánchez, Cristina C; Jares, Pedro P; Rodríguez, Gabriel Felipe GF; Viñolas, Núria N; Reyes, Roxana R; Reguart, Noemí N; Puig-Butillé, Joan Antón JA
Clinical impact of rebiopsy among patients with epidermal growth factor receptor-mutant lung adenocarcinoma in a real-world clinical setting.
Thoracic Cancer
Nam, Yunha Y; Kim, Ho Cheol HC; Kim, Young-Chul YC; Jang, Seung Hun SH; Lee, Kye Young KY; Lee, Shin Yup SY; Lee, Sang Hoon SH; Lee, Sung Yong SY; Yoon, Seong Hoon SH; Ryu, Jeong-Seon JS; Jang, Tae Won TW; Chang, Yoon Soo YS; Kim, Seung Joon SJ; Park, Chan Kwon CK; Lee, Jeong Eun JE; Jung, Chi Young CY; Choi, Chang-Min CM
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario.
International Journal Of Molecular Sciences
Russo, Alessandro A; Franchina, Tindara T; Ricciardi, Giuseppina G; Battaglia, Alessandra A; Picciotto, Maria M; Adamo, Vincenzo V
Better Progression-Free Survival in Elderly Patients with Stage IV Lung Adenocarcinoma Harboring Uncommon Epidermal Growth Factor Receptor Mutations Treated with the First-line Tyrosine Kinase Inhibitors.
Formalin fixation increases deamination mutation signature but should not lead to false positive mutations in clinical practice.
Plos One
Prentice, Leah M LM; Miller, Ruth R RR; Knaggs, Jeff J; Mazloomian, Alborz A; Aguirre Hernandez, Rosalia R; Franchini, Patrick P; Parsa, Kourosh K; Tessier-Cloutier, Basile B; Lapuk, Anna A; Huntsman, David D; Schaeffer, David F DF; Sheffield, Brandon S BS
Clinical mutational profiling of 1006 lung cancers by next generation sequencing.
Oncotarget
Illei, Peter B PB; Belchis, Deborah D; Tseng, Li-Hui LH; Nguyen, Doreen D; De Marchi, Federico F; Haley, Lisa L; Riel, Stacy S; Beierl, Katie K; Zheng, Gang G; Brahmer, Julie R JR; Askin, Frederic B FB; Gocke, Christopher D CD; Eshleman, James R JR; Forde, Patrick M PM; Lin, Ming-Tseh MT
Circulating-free DNA Mutation Associated with Response of Targeted Therapy in Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer.
Chinese Medical Journal
Ye, Qing Q; Qi, Fan F; Bian, Li L; Zhang, Shao-Hua SH; Wang, Tao T; Jiang, Ze-Fei ZF
Different prognostic impact of STK11 mutations in non-squamous non-small-cell lung cancer.
Oncotarget
Pécuchet, Nicolas N; Laurent-Puig, Pierre P; Mansuet-Lupo, Audrey A; Legras, Antoine A; Alifano, Marco M; Pallier, Karine K; Didelot, Audrey A; Gibault, Laure L; Danel, Claire C; Just, Pierre-Alexandre PA; Riquet, Marc M; Le Pimpec-Barthes, Françoise F; Damotte, Diane D; Fabre, Elisabeth E; Blons, Hélène H
EGFR Exon 18 Mutations in East Asian Patients with Lung Adenocarcinomas: A Comprehensive Investigation of Prevalence, Clinicopathologic Characteristics and Prognosis.